Research: UCB, Inc.

Articles found below have been submitted through various PR and news sources and don’t necessary reflect the views of SalesTrax or its employees.

Pharmaceutical Business Review

2009-08-27 16:03
UCB, Immunomedics Release Results Of Epratuzumab Phase IIb Study
Patients in this study had moderate-to-severe active disease in multiple organ systems